Ki-67's ability to regulate the CSC population may be key to understanding how cancers with high expression of Ki-67 can lead to a robust clinical response, yet still be associated with worse prognosis due to a short time to progression (Figure 6d). This evidence concerns the gene MKI67 and cancer.